OSLO/LONDON, 08 March 2022: EXACT THERAPEUTICS AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today provides an update regarding the phase I ACTIVATE study. Read more…
Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny Pharma”), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces a conditional fundraising of up to approximately £7.0 million (before expenses) comprising the Placing, the Subscription and the Open Offer. The net proceeds of the Fundraising will allow the […]
Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]
Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial […]
March 1, 2022 Deal value of US$ 1 billion with US$ 130 million upfront Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing Syndesi’s lead program SDI-118 to be accelerated by AbbVie to the benefit of patients suffering from cognitive impairment associated with a range of neurodegenerative and […]
